A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Launched by NURIX THERAPEUTICS, INC. · Apr 1, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called NX-2127 for adults with certain types of advanced B-cell cancers, such as Chronic Lymphocytic Leukemia (CLL) and various types of lymphoma. The goal of the study is to see how safe this treatment is and how well it works against these cancers. It is currently looking for participants who are at least 18 years old and have measurable disease that requires treatment. Eligible patients should have already tried other therapies without success and must not have certain health conditions that could interfere with the study.

Participants in this trial can expect to receive NX-2127 and will be closely monitored for any side effects and how well the treatment is helping their cancer. The trial is open to both men and women, and those who are able to have children must use contraception during the study. This is an important opportunity for patients with limited treatment options to potentially benefit from a new therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must be ≥ 18 years of age
• • Patients must have measurable disease per disease-specific response criteria
• • Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)
• • Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)
• • Adequate organ and bone marrow function
• • Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol
• Inclusion Criteria for Patients in Phase 1a:
• • Have histologically confirmed R/R CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL
• • Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit
• • Must require systemic therapy
• Inclusion Criteria for Patients in Phase 1b:
• * Must have one of the following histologically documented R/R B-cell malignancies:
• • CLL/SLL whose disease has failed treatment with a BTKi;
• • MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen
• • FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi
• • PCNSL whose disease failed at least 1 prior line of treatment
• • DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible)
• Exclusion Criteria:
• • Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
• • History of known/suspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)
• • Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
• • Bleeding diathesis, or other known risk for acute blood loss
• • Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug
• • Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)
• • Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).
• • Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible
• • Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug
• • Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \> 350/mm3 and undetectable viral load) are eligible.
• • Current active liver disease from any cause
• • Active viral reactivation (e.g., CMV or EBV)
• • Use of systemic corticosteroids exceeding 20 mg/day prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg/day prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.
• • Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study
• • Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug
• • Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days